Welcome to our dedicated page for Curevac B.V. SEC filings (Ticker: CVAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the science is exciting—decoding the paperwork is not. CureVac’s SEC reports are packed with Phase 3 trial readouts, collaboration milestones with GSK and granular R&D spending that can top hundreds of millions. Finding where the cash runway, vaccine efficacy data or milestone payments sit inside a 300-page filing can feel like lab work without the lab.
Stock Titan solves that problem. Our AI engine transforms every CureVac annual report 10-K simplified, each CureVac quarterly earnings report 10-Q filing and any CureVac 8-K material events explained into clear language you can skim in minutes. Want to follow CureVac insider trading Form 4 transactions? Real-time alerts flag executive buys and sells the moment the document hits EDGAR—no manual refresh needed. The platform also stitches together CureVac proxy statement executive compensation numbers so you understand how leadership incentives align with the mRNA pipeline.
Whether you’re benchmarking cash burn against clinical timelines or checking CureVac Form 4 insider transactions real-time before a vaccine data release, our coverage is complete. You’ll see every filing type—10-K, 10-Q, 8-K, S-3, DEF 14A—plus concise AI-powered summaries that surface R&D cost trends, revenue from collaboration agreements and updates on oncology candidates. Use our CureVac earnings report filing analysis to compare quarter-over-quarter progress, or rely on understanding CureVac SEC documents with AI to spot red flags long before the market reacts. Complex biotech disclosures, clarified.
CureVac filed a Form 6-K reporting the completion of its annual general meeting of shareholders held on June 26, 2025. The filing primarily serves to notify the submission of voting results from the meeting.
Key Points:
- The company submitted final tabulation of shareholder votes from its annual general meeting
- Document was signed by CEO Alexander Zehnder
- Filing includes Exhibit 99.1 containing the detailed voting results
- Company confirms it files annual reports under Form 20-F
The filing is purely administrative in nature, serving as a notice of foreign private issuer. The information provided in this Form 6-K is not deemed "filed" under Section 18 of the Securities Exchange Act and does not carry the associated liabilities or incorporation by reference under the Securities Act of 1933 or Exchange Act.
CureVac N.V. (CVAC) filed a Form 6-K to notify investors that it issued a press release on June 24, 2025 detailing the voting results from its Annual General Meeting of shareholders. No financial performance metrics, strategic transactions, or operational updates were included in the filing. The company also clarified that the information, including Exhibit 99.1 (the press release), is furnished—not filed—and therefore is not subject to Section 18 liabilities of the Exchange Act nor incorporated by reference into other SEC filings.
FAQ
What is the current stock price of Curevac B.V. (CVAC)?
What is the market cap of Curevac B.V. (CVAC)?
What is CureVac B.V. known for?
When was CureVac founded?
What are the primary areas of focus for CureVac?
How does CureVac generate its therapeutic innovations?
What role do collaborations play in CureVac's strategy?
How is CureVac positioned within the biotech industry?
What are some key highlights of their clinical pipeline?
How does CureVac demonstrate its commitment to research quality?
